Recent Finacing
Recent Raise
Nuevocor, a Singapore-headquartered biotech, develops AAV-based gene therapies using its PrOSI platform; lead program NVC-001 targets LMNA-related dilated cardiomyopathy with a planned Phase 1/2 trial.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Nuevocor.
